Planegg-Martinsried, Germany, 19 October 2023 – 4SC AG (4SC or “the Company”) (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today provided a business update for the three months ended 30 September 2023, as well as its current outlook. The full report is available […]
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODD benefits include 10 years’ market exclusivity in the European Union The Marketing Authorisation Application (MAA) for Kinselby (resminostat) in the EU remains on track for filing in Q1 2024 Planegg-Martinsried, Germany, 18 October 2023 – 4SC […]
Maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change current clinical practice RESMAIN is one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to-date Resminostat (Kinselby) as a maintenance treatment for advanced CTCL, is clinically proven to postpone disease progression in patients – a new treatment […]
Planegg-Martinsried, Germany, 15 September 2023 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that renowned dermato-oncology key opinion leader and study investigator, Professor Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will give an oral presentation on the findings from […]
Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survival in CTCL patients and risk reduction of 38% compared to placebo Marketing Authorization Application for resminostat and nominated trade name of Kinselby accepted by EMA Kinselby uniquely positioned as maintenance treatment for CTCL Cash runway to Q3 2024 Planegg-Martinsried, […]
